-
FDA sets May 2027 decision date on AMT-130 gene therapy for HD
4 min read
Latest News
-
Huntington's disease therapeutics conference 2019 – Day 3
12 min read
New insights into the huntingtin protein, and further progress in turning genetic quirks that modify the course of HD into treatments, on the final day of the therapeutics conference
-
Huntington's disease therapeutics conference 2019 – Day 2
5 min read
New tools to bridge the gap between the lab and patients in our update from day 2 of the 2019 HD Therapeutics conference
-
Huntington's disease therapeutics conference 2019 – Day 1
9 min read
HDBuzz reports from the annual Huntington’s disease therapeutics conference in Palm Springs
-
Huntington's disease goes viral as UniQure inches ahead in gene therapy race
9 min read
FDA grants “Investigational New Drug” status to Huntingtin-lowering gene-therapy agent AMT-130, clearing path to human trials in Huntington’s Disease patients
-
Advances on many fronts in the battle against the protein that causes Huntington's disease
11 min read
This fall sees exciting announcements from a number of companies focused on novel Huntingtin Lowering technologies, including Wave, PTC and Voyager
-
HDSA FAQ on the Roche/Genentech RG6042 program
18 min read
HDSA's frequently asked questions factsheet about the huntingtin-lowering trial ASO program was so good we stole it (with permission)
-
Kids sometimes get Huntington’s disease too
6 min read
Finally, a big study that shows what childhood HD looks like. This will help us work out if new drugs work in children too
-
Roche announces details of its 'pivotal' huntingtin-lowering study
10 min read
The GENERATION-HD1 trial will test whether RG6042 – formerly Ionis-HTTRx – slows the progression of Huntington's disease
-
Disappointing news from LEGATO-HD trial of laquinimod in Huntington's disease
5 min read
The LEGATO-HD trial of laquinimod did not slow progression of Huntington's disease. Here's the lowdown.
-
HDBuzz Enrolls in Enroll-HD
12 min read
As promised, HDBuzz's Jeff Carroll finally signed up for the Enroll-HD study. Learn more about this important global HD "observational study" here.
HDBuzz Trial Tracker
FDA accepts BLA for Priority Review, with a target decision date of 1 May 2027.
Show 8 more Show less
Updates from the ongoing Phase 3 INVEST-HD trial of votoplam
Updates from the Phase 1b/2a REGEN4HD trial of neural stem cell therapy hNSC-01
Updates from the ongoing Phase 2/3 FALCON-HD trial of SKY-0515
